Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial

被引：7
|
作者：
Guttman-Yassky, E. [1 ,9 ]
Bahadori, L. [2 ]
Brooks, L. [3 ]
Clark, K. L. [3 ]
Grindebacke, H. [4 ]
Ho, C. N. [5 ]
Katial, R. [6 ,7 ]
Pham, T. -H. [8 ]
Walton, C. [3 ]
Datto, C. J. [2 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA
[3] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Cambridge, England
[4] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gothenburg, Sweden
[5] AstraZeneca, Patient Ctr Sci, BioPharmaceut Med, Gaithersburg, MD USA
[6] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA
[7] Natl Jewish Hlth, Denver, CO USA
[8] AstraZeneca, Translat Sci & Expt Med, Early Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA
[9] Icahn Sch Med Mt Sinai, Kimberly & Er J Waldman Dept Dermatol, 1425 Madison Ave,Box 1047, New York, NY 10029 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 10期
关键词：
EFFICACY; SAFETY;
D O I：
10.1111/jdv.19195
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E1211 / E1214
页数：4
相关论文
共 50 条
  • [21] Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
    Langley, Richard G.
    Feldman, Steven R.
    Han, Chenglong
    Schenkel, Brad
    Szapary, Philippe
    Hsu, Ming-Chun
    Ortonne, Jean-Paul
    Gordon, Kenneth B.
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (03) : 457 - 465
  • [22] Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial
    D'Haens, Geert
    Stardelova, Kalina Grivcheva
    Sadiku, Edite
    Kizlova, Natallia
    Skybalo, Syitlana
    Shehovtsova, Yulia
    Abramescu, Mirela
    Vitt, Daniel
    Kohlhof, Hella
    Muehler, Andreas
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (03)
  • [23] DaxibotulinumtoxinA for injection to treat moderate or severe glabellar lines: A randomized, multicenter, Phase III, double-blind, placebo-controlled trial in China
    Xie, Yun
    Liu, Quanzhong
    Li, Li
    Wang, Baoxi
    Sun, Jiaming
    Zhao, Hongyi
    Guo, Qing
    Su, Juan
    Fan, Xiaojing
    Wang, Hui
    Ge, Lei
    Wang, Xingli
    Li, Qingfeng
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2024, 99 : 67 - 75
  • [24] Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial
    Paul, C.
    Reich, K.
    Gottlieb, A. B.
    Mrowietz, U.
    Philipp, S.
    Nakayama, J.
    Harfst, E.
    Guettner, A.
    Papavassilis, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (12) : 1670 - 1675
  • [25] Evaluation of the effect ofSilybum marianumextract on menopausal symptoms: A randomized, double-blind placebo-controlled trial
    Saberi, Zohreh
    Gorji, Narjes
    Memariani, Zahra
    Moeini, Reihaneh
    Shirafkan, Hoda
    Amiri, Mania
    PHYTOTHERAPY RESEARCH, 2020, 34 (12) : 3359 - 3366
  • [26] Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
    Werth, Victoria P.
    Fleischmann, Roy
    Robern, Michael
    Touma, Zahi
    Tiamiyu, Iyabode
    Gurtovaya, Oksana
    Pechonkina, Alena
    Mozaffarian, Afsaneh
    Downie, Bryan
    Matzkies, Franziska
    Wallace, Daniel
    RHEUMATOLOGY, 2022, 61 (06) : 2413 - 2423
  • [27] Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
    Bagel, Jerry
    Lynde, Charles
    Tyring, Stephen
    Kricorian, Gregory
    Shi, Yifei
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (01) : 86 - 92
  • [28] Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
    Seong-Ho Koh
    Hyuk Sung Kwon
    Seong Hye Choi
    Jee Hyang Jeong
    Hae Ri Na
    Chan Nyoung Lee
    YoungSoon Yang
    Ae Young Lee
    Jae-Hong Lee
    Kyung Won Park
    Hyun Jeong Han
    Byeong C. Kim
    Jin Se Park
    Jee-Young Lee
    Sangjae Kim
    Kyu-Yong Lee
    Alzheimer's Research & Therapy, 13
  • [29] Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
    Koh, Seong-Ho
    Kwon, Hyuk Sung
    Choi, Seong Hye
    Jeong, Jee Hyang
    Na, Hae Ri
    Lee, Chan Nyoung
    Yang, YoungSoon
    Lee, Ae Young
    Lee, Jae-Hong
    Park, Kyung Won
    Han, Hyun Jeong
    Kim, Byeong C.
    Park, Jin Se
    Lee, Jee-Young
    Kim, Sangjae
    Lee, Kyu-Yong
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [30] Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
    Torii, Hideshi
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2010, 59 (01) : 40 - 49
12345